Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

MEMY

252 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 »» | Laatste | Omlaag ↓
  2. [verwijderd] 2 november 2006 16:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Het is een posting van Yahoo
    De datum is niet in gevuld in het formulier
    messages.finance.yahoo.com/mb/MEMY

    De koers staat nu 2,37

    aardige vollume voor memy 786.320
    quote:

    Smartie2000 schreef:

    [quote=The Wishbone]
    xml.10kwizard.com/filing_raw.php?repo...
    [/quote]

    Wat wil dit zeggen Wish/iemand?
  3. Smartie2000 2 november 2006 16:34

    • Smartie2000

      Lid sinds: 07 feb 2006

      Laatste bezoek: 27 jul 2024

    • Aanbevelingen

      Ontvangen: 10

      Gegeven: 4

    •    Aantal posts: 158

    quote:

    The Wishbone schreef:

    Het is een posting van Yahoo
    De datum is niet in gevuld in het formulier
    messages.finance.yahoo.com/mb/MEMY

    De koers staat nu 2,37

    aardige vollume voor memy 786.320
    [quote=Smartie2000]
    [quote=The Wishbone]
    xml.10kwizard.com/filing_raw.php?repo...
    [/quote]

    Wat wil dit zeggen Wish/iemand?
    [/quote]
    Een snelle plik op het sec formulier leert dat een aandeelhoudersvergadering wordt belegd. De aandeelhouders moeten kennelijk om een of andere reden geconsulteerd worden.

    Aan het koersverloop is er goed nieuws.
  4. [verwijderd] 2 november 2006 16:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    $2 mln milestone from Roche related to MEM 3454 Co announces that Roche has elected to maintain its option to obtain an exclusive license for MEM 3454, the lead compound from the cos' alliance focused on the discovery and clinical development of nicotinic alpha-7 receptor agonists for the treatment of neurological and psychiatric disorders. This decision was triggered by Memory Pharmaceuticals' Phase 1 work on MEM 3454, which satisfied a set of criteria that was pre-defined by Roche, and will result in a $2 mln milestone payment to Memory Pharmaceuticals. Under the terms of the nicotinic alpha-7 alliance, Memory Pharmaceuticals is responsible for the development of MEM 3454 through Phase 2a clinical trials. Roche has the right to obtain an exclusive license for MEM 3454 following the completion of Phase 2a clinical trials for that compound. Roche maintains this right through the development process by making three payments to Memory Pharmaceuticals upon its achievement of certain pre-established development milestones.

    Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
  7. [verwijderd] 3 november 2006 21:43

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Memory Pharmaceuticals Corp., which develops drugs to treat memory and cognitive problems, saw trading surge to 1.7 million shares from an average daily volume of 410,000.

    The company wants to issue 5 million shares to certain institutional investors at $1.11 each, it said in a filing with the Securities and Exchange Commission. The plan requires approval from shareholders.

    Shares added 21 cents, or 9.2 percent, to $2.38.

    biz.yahoo.com/ap/061102/apfn_apfn_vol...
  9. [verwijderd] 9 november 2006 12:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Memory Pharmaceuticals Reports Third Quarter 2006 Financial Results
    Thursday November 9, 6:30 am ET

    MONTVALE, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News), a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system (CNS) conditions, today reported its financial results for the three and nine months ended September 30, 2006.

    "Over the past few months, we have strengthened our financial position and reported important advancements with our clinical program for MEM 1003 and our other preclinical programs," said Jim Sulat, President and Chief Executive Officer. "As a result of continued progress with our preclinical programs, we achieved key milestones and secured research funding commitments for 2007 from our partners, which together with our recent PIPE financing will provide us with the resources to complete our ongoing proof-of-concept trials for MEM 1003 in Alzheimer's disease and bipolar disorder, as well as our planned Phase 2a trial for MEM 3454."

    For the three months ended September 30, 2006, the Company reported a net loss of $9.8 million, or $0.26 per share, compared to a net loss of $11.2 million, or $0.42 per share, for the comparable period in 2005. Net income includes a non-cash gain of $0.3 million related to the warrants issued in the Company's September 2005 private placement and a non-cash charge of $0.7 million related to Statement of Financial Accounting Standards 123R, "Share-based Payments" (SFAS 123R). For the three months ended September 30, 2006, after removing the effects of the two non-cash items noted above, the Company's non-GAAP net loss was $9.5 million, or $0.25 per share.

    For the nine months ended September 30, 2006, the Company reported a net loss of $16.4 million, or $0.43 per share, compared to a net loss of $28.0 million, or $1.24 per share, for the comparable period in 2005. The 2006 net loss includes a non-cash gain of $5.8 million related to the warrants issued in the Company's September 2005 private placement and a non-cash charge of $2.1 million related to SFAS 123R. For the nine months ended September 30, 2006, after removing the effects of the two non-cash items noted above, the Company's non-GAAP net loss was $20.1 million, or $0.53 per share.

    In connection with the Company's September 2005 private placement, the Company agreed to file a registration statement with the Securities and Exchange Commission to register for resale the shares of common stock, and the shares of common stock issuable upon the exercise of the warrants, sold in the private placement. The Company is required to keep this registration statement effective for a maximum of two years and will be required to pay certain cash penalties if it does not meet its registration obligations. As a result of the potential magnitude for penalties if the Company fails to meet this obligation, GAAP requires that the fair value of the warrants issued in the private placement be classified as a liability on the Company's Balance Sheet, with the change in fair value recognized in the Company's Statement of Operations as unrealized gains or losses. In calculating non-GAAP earnings, management excludes any unrealized gains or losses on the warrants in addition to the expense associated with SFAS 123R. A reconciliation of GAAP to non-GAAP earnings is presented in the tables at the end of this press release.

    The Company believes that certain non-GAAP measures, when presented in conjunction with comparable GAAP measures, are useful for evaluating the Company's operating performance. Internally, the Company uses this non-GAAP information as an indicator of business performance and evaluates management's effectiveness with specific reference to these indicators. Non-GAAP measures should be considered in addition to, not as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Unless otherwise noted, all numbers presented herein are in accordance with GAAP.

    For the three months ended September 30, 2006, the Company reported revenue of $2.0 million, compared to revenue of $2.5 million for the same period in 2005. For the nine months ended September 30, 2006, revenue was $6.7 million, compared to revenue of $7.4 million for the same period in 2005. Revenue relates to the Company's two agreements with Hoffmann La-Roche, one of which is for the development of PDE4 inhibitors and the other for the development of nicotinic alpha-7 agonists, and the Company's agreement with Amgen for the development of PDE10 inhibitors. This revenue includes the amortization of upfront non-refundable fees and milestone payments, in addition to payments received for research and development funding.

    Research and development expenses for the third quarter of 2006 were $10.0 million compared to $7.8 million for the comparable period in 2005. The $2.2 million increase included $2.3 million in increased costs associated with the clinical development of MEM 1003 and MEM 3454 and $0.2 million in increased personnel and personnel-related costs. Personnel and personnel-related costs in 2006 include a $0.4 million non-cash compensation charge related to SFAS 123R.

    Research and development expenses for the nine months ended September 30, 2006 were $23.3 million compared to $25.5 million for the nine months ended September 30, 2005. The $2.2 million decrease included $1.0 million in reduced costs associated with the clinical development of MEM 1003 and MEM 3454, $1.3 million related to a 2005 non-cash compensation charge for the modification of vested stock options held by our former president and $0.9 million in reduced personnel and personnel-related costs. The decrease was partially offset in 2006 by a $1.1 million non-cash compensation charge related to SFAS 123R.

    General and administrative expenses for the three months ended September 30, 2006 were $2.4 million, compared to $2.1 million for the comparable period in 2005. The current period includes a $0.1 million reduction in legal and patent fees offset by a $0.4 million increase in personnel and personnel-related costs. Included in the personnel related costs in 2006 is a non-cash compensation charge of $0.3 million related to SFAS 123R.

    General and administrative expenses for the nine months ended September 30, 2006 were $6.7 million compared to $6.4 million for the nine months ended September 30, 2005. The current period includes a non-cash compensation charge of $1.0 million related to SFAS 123R partially offset by decreased personnel costs of $0.3 million and decreased legal and patent fees of $0.4 million.

    At September 30, 2006, the Company had cash, cash equivalents and marketable securities of approximately $24.9 million, compared to $44.1 million at December 31, 2005. In early October, the Company announced that it had entered into a definitive purchase agreement for a private placement of common stock and warrants. The first tranche of the financing closed on October 16, 2006, and resulted in gross proceeds to Memory Pharmaceuticals of $26.7 million. The Company expects that its existing cash, cash equivalents, and marketable securities, together with payments required to be made under its collaboration agreements, plus the proceeds of the first tranche of the financing in October, will be
  10. [verwijderd] 13 november 2006 18:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Wat een aandeel zo duikt die naar beneden,zo staat die weer in de plus.
    Niet echt stabiele, maar wel een traders aandeel.
    Op de juiste tijd er in en er weer uit .
    Het blijf moeilijk om deze ritme op te pakken.
    Vriendelijke groet,
  13. [verwijderd] 5 januari 2007 18:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    The Wishbone schreef:

    3,16

    Hoeveel winst is dit

    Komt van de 0,80 cent af.

    Vriendelijke groet,

    Je zegt het verkeerd, komt van ruim boven de 2, toen terug naar 0,80 door tegenvallende resultaten, en inmiddels krachtig aan een herstel begonnen! Die amerikanen zijn helemaal los! Heb een tijdje in MEMY gezeten, echter uitgestapt na de tegenvallende resultaten en eigenlijk daarna uit het oog verloren en niet meer op tijd op de trein gestapt!! Maar in ieder geval voor de zittenblijvers: good luck and congratulations!
  17. Smartie2000 7 februari 2007 15:17

    • Smartie2000

      Lid sinds: 07 feb 2006

      Laatste bezoek: 27 jul 2024

    • Aanbevelingen

      Ontvangen: 10

      Gegeven: 4

    •    Aantal posts: 158

    Memy blijft dag na dag stijgen. Intraday wordt soms flink aan de boom geschut maar bij sluiting altijd hoger. Op level II te zien wordt getracht de koer laag te houden.

    finance.yahoo.com/q/bc?s=MEMY&t=3m&l=...

    Waarom de koers stijgt is niet geheel duidelijk. Wellicht is er voorkennis mbt de voortgang van het onderzoek van MEM 3454 (fase 2a) dat in het eerste kwartaal 2007 zal aanvangen of misschien is er een overname op handen. Ik blijf voorlopig zitten.
  19. Smartie2000 9 februari 2007 16:15

    • Smartie2000

      Lid sinds: 07 feb 2006

      Laatste bezoek: 27 jul 2024

    • Aanbevelingen

      Ontvangen: 10

      Gegeven: 4

    •    Aantal posts: 158

    quote:

    DieGroeneGigant schreef:

    Wat een mooie rit. 4.52 weerstand.

    print.chartnet.nl/Show.cgi?Img=1D7D46...
    Bedankt voor het grafische werk Groene, dat wordt altijd op prijsgesteld.

    De door jou gestelde weerstand is gebroken; tijd om verder opwaarts te gaan.

    Eigenlijk geen idee wat er aan de hand is, een op handen zijnde overname? Maar het is zeker een mooie rit. Hoe hoger, hoe beter het uitzicht.
252 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.192
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.501
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.648
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.991
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.035
Alfen 16 24.319
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.709
AMG 971 133.042
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 482
Antonov 22.632 153.605
Aperam 92 14.901
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.551
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.977
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.609
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390